| 1. |
Eswaran H, Googe P, Vedak P, et al. Livedoid vasculopathy: a review with focus on terminology and pathogenesis. Vasc Med, 2022, 27(6): 593-603.
|
| 2. |
Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol, 2006, 142(11): 1481-1482.
|
| 3. |
Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: a review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol, 2016, 82(5): 478-488.
|
| 4. |
Bilgic A, Ozcobanoglu S, Bozca BC, et al. Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management. Int J Womens Dermatol, 2021, 7(5Part A): 588-599.
|
| 5. |
Kunz HE, Hart CR, Gries KJ, et al. Adipose tissue macrophage populations and inflammation are associated with systemic in flammation and insulin resistance in obesity. Am J Physiol Endocrinol Metab, 2021, 321(1): E105-E121.
|
| 6. |
Zatterale F, Longo M, Naderi J, et al. Chronic adipose tissue in flammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol, 2019, 10: 1607.
|
| 7. |
姚慶, 王浩安, 高文婷, 等. 脂肪細胞分泌的炎癥因子及相關信號通路介導的肥胖和胰島素抵抗. 大連醫科大學學報, 2022, 44(4): 341-345.
|
| 8. |
Bouchnita A, Miossec P, Tosenberger A, et al. Modeling of the effects of IL-17 and TNF-α on endothelial cells and thrombus growth. C R Biol, 2017, 340(11/12): 456-473.
|
| 9. |
聞娟. 青斑樣血管病 42 例臨床分析. 鄭州: 鄭州大學, 2020.
|
| 10. |
王深明, 王斯文. 重視下肢慢性靜脈功能不全的規范化診治. 中國實用外科雜志, 2023, 43(12): 1344-1347, 1397.
|
| 11. |
Zhang H, Chen J, Wu N, et al. Refractory livedoid vasculopathy in a child successfully treated with baricitinib. Dermatol Ther, 2022, 35(8): e15659.
|
| 12. |
Xiao Y, Wang Y, Gu Y, et al. Refractory livedoid vasculopathy successfully treated with baricitinib. Int J Dermatol, 2023, 62(9): 1204-1205.
|
| 13. |
Song X, Tu P. Treatment of livedoid vasculopathy with baricitinib. JAMA Dermatol, 2022, 158(5): 587-589.
|
| 14. |
葉慧, 朱君慧, 陳偉鋒, 等. 阿布昔替尼治療青斑樣血管病一例. 中國麻風皮膚病雜志, 2024, 40(3): 196-198.
|
| 15. |
Huang XW, Zheng HX, Wang ML, et al. Adalimumab in treating refractory livedoid vasculopathy. Vaccines (Basel), 2022, 10(4): 549.
|
| 16. |
Dong L, Li Q, Yu Y, et al. Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: case report and literature review. Dermatol Ther, 2022, 35(9): e15666.
|
1/5
WeChat